New option available for Alzheimer’s patients as FDA approves expanded drug use

The U.S. Food and Drug Administration has green-lit the first-ever non-antipsychotic drug treatment for agitation in Alzheimer’s disease patients.

The drug, Auvelity, was originally FDA-approved in 2022 for treating adults with major depressive disorder. Most recently, its use has been expanded for agitation associated with dementia.

Agitation is a common and "distressing" symptom in adults with Alzheimer’s, according to the agency. The condition is characterized by excessive motor activity, or verbal or physical aggression.